

Ultrasound therapy for plantar fasciitis. A double blind randomised placebo controlled trial

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 15/05/2012	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Cathy Speed

Contact details

Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 586518
cathy.speed@btinternet.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0544093542

Study information

Scientific Title

Study objectives

Ultrasound in plantar fasciitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Musculoskeletal Diseases: Plantar fasciitis

Interventions

To evaluate the effects of ultrasound in the treatment of plantar fasciitis. Adult subjects with plantar fasciitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will all be blinded. Outcome measures will be recorded at 6 weeks and at 4 months from baseline. These will include an ankle and foot score and pain (primary measures), isokinetic strength of ankle plantar flexion and dorsiflexion, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

12/10/2000

Completion date

12/10/2003

Eligibility**Key inclusion criteria**

200 (PROJ)

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

200

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

12/10/2000

Date of final enrolment

12/10/2003

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Box No 204

Cambridge

United Kingdom

CB2 2QQ

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Other

Funder Name

Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2003		Yes	No